Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

Basit Öğe Kaydı
dc.authorscopusid7006046625
dc.authorscopusid8922379100
dc.contributor.authorErdogan B.
dc.contributor.authorCicin I.
dc.date.accessioned2024-06-12T10:24:45Z
dc.date.available2024-06-12T10:24:45Z
dc.date.issued2019
dc.description.abstractBreast cancer bone metastasis causes severe morbidity and is commonly encountered in daily clinical practice. It causes pain, pathologic fractures, spinal cord, and other nerve compression syndromes and life-threatening hypercalcemia. Breast cancer metastasizes to the bone through a complicated process that involves numerous molecules. Metastatic cells disrupt normal bone turnover and create a vicious cycle. All treatment effort is directed to breaking this vicious cycle. Bisphosphonates have been used safely for more than two decades. As a group, bisphosphonates delay the time to the first skeletal-related event and reduce pain. However, they do not prevent the development of bone metastasis in patients with no bone metastasis and do not prolong survival. The receptor activator for nuclear factor ?B ligand inhibitor denosumab also delays the time to the first skeletal-related event and reduces the skeletal morbidity rate. Radionuclides are another treatment option for bone pain. © Springer Nature Switzerland AG 2019.en_US
dc.identifier.doi10.1007/978-3-030-16792-9_42
dc.identifier.endpage617en_US
dc.identifier.isbn9783030167929
dc.identifier.isbn9783030167912
dc.identifier.scopus2-s2.0-85184424804en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage607en_US
dc.identifier.urihttps://doi.org/10.1007/978-3-030-16792-9_42
dc.identifier.urihttps://hdl.handle.net/20.500.14551/15988
dc.identifier.volume2en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Science+Business Mediaen_US
dc.relation.ispartofBreast Disease: Management and Therapies: Volume 2, Second Editionen_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectA?ß3 Integrin; Bisphosphonate; Cadherin-11; Cathepsin K; Clodronate; Conjunctivitis; Denosumab; E-Selectin; Episcleritis; Farnesyl Pyrophosphate Synthase Enzyme; Hypocalcemia; Ibandronate; Insulin-Like Growth Factor 1 (Igf1); Interleukin 11 (Il-11); Interleukin 6 (Il-6); Intracellular Adhesion Molecule (Icam-1); Iritis; Macrophage Colony-Stimulating Factor (M-Csf); Mevalonate Pathway; Nephrotoxicity; Odanacatib; Osteonecrosis Of The Jaw (Onj); P-Selectin; Pamidronate; Parathyroid Hormone-Related Peptide (Pthrp); Phosphorus-32 (P-32); Prenylation; Prostaglandin E2 (Pge2); Radionuclide; Rhenium-186 Hydroxyethylidene Diphosphonate (Re-186); Samarium-153 Lexidronam (Sm-153); Saracatinib; Scleritis; Src. Dasatinib; Strontium-89 Hydrochloride (Sr-89); Uveitis; Vascular Cell Adhesion Molecule (Vcam-1); Zoledronic Aciden_US
dc.titleBone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclidesen_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu